Pharminent

Japan Grants Priority Review to AbbVie’s Investigational Regimen for all Major HCV Genotypes

NewsThe Japanese MHLW designates priority review to certain medicines based on the clinical usefulness of the treatment and severity of the disease. Topics: Drug Pipeline http://www.dddmag.com/news/2017/03/japan-grants-priority-review-abbvies-investigational-regimen-all-major-hcv-genotypes

Filed under: HCV